-
Symeres Appoints Gabriella Gentile as Chief Operating Officer to Drive Transatlantic Growth
We are pleased to announce the appointment of Gabriella Gentile as […]
-
Symeres Announces Acquisition of DGr Pharma
We are delighted to announce the acquisition of DGr Pharma, an […]
-
Insights into Drug Discovery and Development 2025
Here we interview our Director of Medicinal Chemistry, Anita Wegert, for her insights into drug discovery and development for 2025. This interview was conducted an interviewer from the Drug Discovery and Development Europe event and we were able to share our expertise. Curious how our insights can help your next project?
-
Symeres and Yoneda Labs Use AI to Optimize Cross-Coupling Reactions
San Francisco, May 29, 2025 – Yoneda Labs, a leader in computational tools for reaction optimization, has successfully collaborated with Symeres, a leading transatlantic, small molecule contract research and manufacturing organization. The aim was to optimize transition metal catalyzed cross-coupling reactions to improve reaction yield and efficiency utilizing Yoneda Labs’ cutting-edge software.
Latest patents
-
Novel intermediate in production of oxoisoquinoline derivative with BTK inhibitory activity
Number: WO2024134859 (PCT/JP2022/047526)
-
Compounds and their use as PDE4 activators
Number: WO/2024/038129
-
Compounds and their use as PDE4 activators
Number: WO/2024/038128
Latest publications
-
Silicon-based Linkers for Tunable Acid-Sensitive Drug Release from Polymeric Nanoparticles
Article: Chemistry Europe. 2024 Dec 11:e202403589
-
Rare Case of Polymorphism in the Binary System of Enantiomers of a Praziquantel Derivative
Article: Org. Process Res. Dev. 2024, 28, 4, 1224–1232
-
Towards Multitargeted Ligands as Pain Therapeutics: Dual Ligands of the Cavα2δ-1 Subunit of Voltage-Gated Calcium Channel and the μ-Opioid Receptor
Article: ChemMedChem 2024, e202300473
Feel free to contact us!
Curious to know more about what can we do for you? Get in touch and let’s start a conversation.
